Home >> Tag Archives: Luminex—

Tag Archives: Luminex—

Luminex acquires MilliporeSigma’s flow cytometry portfolio

Jan. 14, 2019—Luminex has completed its acquisition of MilliporeSigma’s flow cytometry portfolio for $75 million. The flow cytometry portfolio includes the Amnis family of imaging flow cytometry products for cell-based analysis and the Guava portfolio of microcapillary flow cytometry systems. “The Amnis and Guava products complement our wide range of existing flow-based offerings, further differentiating our portfolio and ensuring we ...

Read More »

Luminex offers white paper on preventing CDI

A white paper titled “Can Global Testing for C. difficile Carriers Help to Prevent Healthcare-associated CDI?” from Luminex discusses the results of two recent studies that show that performing C. difficile testing only in patients with clinically significant diarrhea may be missing an opportunity to prevent CDI transmission from asymptomatic carriers. Download the white paper.

Read More »

The aftermath of an overwhelming flu season,
a discussion on lessons learned

Webinar presenters Margie A. Morgan, PhD, D(ABMM), and Gregory J. Berry, PhD, D(ABMM), discuss the impacts of this past year’s flu season. This webinar will empower you to anticipate the impact of another significant flu season, assess your health care system testing needs; and choose the appropriate tests/algorithm for your lab. This on-demand webinar originally broadcast on August 15, 2018.

Read More »

FDA-cleared Bordetella assay, 8/17

August 2017—Luminex received FDA clearance for the Aries Bordetella Assay for direct detection and identification of Bordetella pertussis and Bordetella parapertussis nucleic acid in nasopharyngeal swab specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis.

Read More »

FDA clearance for Aries Bordetella assay

June 5, 2017—Luminex received FDA clearance for the Aries Bordetella Assay for direct detection and identification of Bordetella pertussis and Bordetella parapertussis nucleic acid in nasopharyngeal swab specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis. The company has also achieved CE-IVD marking for the Aries Bordetella Assay, is preparing to submit ...

Read More »

Luminex’s molecular test for flu A/B, RSV cleared

Aug. 23, 2016—Luminex has received FDA clearance for the Aries Flu A/B and RSV Assay. This is the second assay the FDA has cleared for use on the Luminex Aries system. The Aries Flu A/B and RSV Assay delivers results in less than two hours for the detection and differentiation of three key respiratory pathogens (influenza A virus, influenza B ...

Read More »

Luminex lands EUA for molecular Zika test

Aug. 17, 2016—Luminex has received emergency use authorization from the FDA for a multiplex nucleic acid test designed to detect Zika virus RNA in potentially infected patients using their blood serum, plasma, or urine (collected alongside a patient-matched serum or plasma specimen). The test is called the xMap MultiFlex Zika RNA Assay, designed by Luminex partner GenArraytion Inc. In July ...

Read More »

FDA clearance, CE mark for Luminex Aries M1

July 11, 2016—Luminex has received FDA clearance and CE-IVD marking for a new in vitro diagnostic system, the Aries M1. Designed for lower throughput clinical labs, the Aries M1 System is a fully integrated, sample-to-answer platform for performing real-time PCR assays. The Aries M1 is designed to empower satellite clinical laboratories to take advantage of the same benefits as Luminex’s ...

Read More »
X